<DOC>
	<DOCNO>NCT01155635</DOCNO>
	<brief_summary>The purpose study evaluate whether beta-blocker therapy improve 6-year clinical outcome patient ST-segment elevation acute myocardial infarction preserve leave ventricular ejection fraction primary percutaneous coronary intervention .</brief_summary>
	<brief_title>Carvedilol Post-intervention Long-term Administration Large-scale Trial</brief_title>
	<detailed_description>Beta-blocker therapy recommend ST-segment elevation acute myocardial infarction ( STEMI ) current guideline although efficacy patient undergone primary percutaneous coronary intervention ( PCI ) adequately evaluate . The purpose study evaluate whether beta-blocker , carvedilol improve 6-year clinical outcome patient STEMI preserve leave ventricular ejection fraction primary PCI . The design study multicenter , open-label , randomize control trial enrol 1300 patient without exclusion criterion .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients STEMI primary PCI Patients leave ventricular ejection fraction equal 40 % Patients leave ventricular ejection fraction le 40 % Patients contraindication betablocker Patients implantable cardioverter defibrillator Patients endstage malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Adrenergic beta-Antagonists</keyword>
	<keyword>Percutaneous coronary intervention</keyword>
</DOC>